Largecap pharma stocks such as Sun, Aurobindo, Glenmark have climbed 10-16% in June.
The Nifty Pharma index was trading 0.40 per cent down at 9,282 around 3 pm.
Kunal Bothra maintains a positive stance till the time 10,700, a key short term support, is breached.
Nifty opened at 10826, 30 points below its previous close at 10856 yesterday. On the other side of the world, The Federal Reserve raised its fund rate by 25 basis points...
Dramatic Market action in Sun Pharma (NS:SUN) share prices, Stocks rallied the most in nearly 6 months. Short sellers are exiting in panic after US Drug regulators said it may not...
India’s benchmark Nifty saw its first bouts of profit taking today. The index opened almost 32 points below its previous close at 10768. Markets remained volatile in...
| Type | 5 mins | 15 mins | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Strong Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | BUY | Strong Buy | Sell |
| Summary | Strong Buy | Strong Buy | Buy | Strong Buy | Neutral |
Filter Table By:
| Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
|---|---|---|---|---|---|
| Emerging Patterns | |||||
| Deliberation Bearish | 15 | Current | |||
| Doji Star Bearish | 15 | Current | |||
| Gravestone Doji | 15 | Current | |||
| Completed Patterns | |||||
| Engulfing Bearish | 1M | 4 | Feb 18 | ||
| Three Inside Up | 1H | 4 | Jun 20, 2018 11:30 | ||
| Three Black Crows | 1W | 5 | May 13, 2018 | ||
| Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| NSE | 564.10 | 0.00 | 0.00 | 4,435,880 | +0.74% | INR | 20/06 | ||
| NSE | 565.55 | 0.00 | 0.00 | 16,958,700 | +0.69% | INR | 20/06 | ||
| BSE | 564.00 | 0.00 | 0.00 | 297,856 | +0.70% | INR | 20/06 |
| Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| Reliance Industries | 1,019.25 | 1,022.90 | 994.85 | +23.20 | +2.33% | 7.19M | 20/06 | ||
| Tata Steel Ltd | 563.25 | 565.90 | 553.30 | +8.25 | +1.49% | 6.61M | 20/06 | ||
| Bata India | 843.05 | 844.80 | 818.70 | +18.10 | +2.19% | 2.36M | 20/06 | ||
| HDFC Bank | 2,056.15 | 2,058.00 | 2,025.00 | +32.65 | +1.61% | 2.26M | 20/06 | ||
| Vedanta | 228.70 | 230.15 | 225.25 | +4.40 | +1.96% | 17.01M | 20/06 | ||
| Cipla | 602.85 | 622.75 | 600.35 | +1.00 | +0.17% | 9.12M | 20/06 | ||
| Yes Bank | 336.10 | 337.00 | 331.40 | +5.20 | +1.57% | 7.72M | 20/06 | ||
| SBI | 273.30 | 274.75 | 271.10 | +0.70 | +0.26% | 14.00M | 20/06 | ||
| Interglobe Aviation Ltd | 1,136.45 | 1,221.00 | 1,126.35 | -92.20 | -7.50% | 2.73M | 20/06 | ||
| Sun Pharma | 564.10 | 565.70 | 553.10 | +4.15 | +0.74% | 4.44M | 20/06 |
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.
Read More
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
